Advertisement

Topics

Themis Company Profile

07:50 EDT 19th April 2018 | BioPortfolio

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating disease with global outbreak potential. Our innovation in vaccine technology has created a powerful platform and a growing pipeline addressing a broad range of infectious diseases. Together with industrial and academic leaders we work to prevent illness across the globe. For more information, visit http://www.themisbio.com.


News Articles [19 Associated News Articles listed on BioPortfolio]

$37.5 million investment in Austrian vaccines developer Themis Bioscience

A new partnership between Austrian biotech Themis Bioscience and Oslo-based CEPI – the Coalition for…

Themis raises €10mm in Series C round

Themis Bioscience GMBH raised €10mm ($12mm) in its Series C financing led by Global Health Investment Fund, which adds a board member and was joined by returning shareholders aws Gruenderfonds, Omne...

Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II

Chikungunya fever could be the next big global outbreak. Reassuringly, Themis’ vaccine has so far performed well in a Phase II study. Vienna-based biotech, Themis, develops urgently needed vacci...

Austrian Vaccines Biotech Closes €10M Series C to Stop Global Outbreaks

Austrian biotech Themis has received a financial boost for the development of its vaccines against infections like Chikungunya, which could be the next big global outbreak. Themis, which specializes ...

Themis partners with CEPI to develop Lassa, MERS vaccines

CEPI backs Themis to advance Lassa fever, MERS vaccines

Themis & CEPI Enter Collaboration

For advanced vaccine development and manufacturing for Lassa fever and MERS

Dermapharm-Aktie: Auffällige Insiderverkäufe

Grünwald - Bei der Aktie der Dermapharm Holding SE (ISIN: DE000A2GS5D8, WKN: A2GS5D, Ticker-Symbol: DMP) waren zuletzt auffällige Insiderverkäufe zu beobachten. Am 08.02.2018 hat die Themis Beteili...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI

To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in patie...

Companies [2 Associated Companies listed on BioPortfolio]

Themis

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating...

Themis Bioscience

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating...

More Information about "Themis" on BioPortfolio

We have published hundreds of Themis news stories on BioPortfolio along with dozens of Themis Clinical Trials and PubMed Articles about Themis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Themis Companies in our database. You can also find out about relevant Themis Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record